<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8900963</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1466</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Neurobiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Neurobiol.</journal-id>
<journal-title-group>
<journal-title>Molecular neurobiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-7648</issn>
<issn pub-type="epub">1559-1182</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30288694</article-id>
<article-id pub-id-type="pmc">6447488</article-id>
<article-id pub-id-type="doi">10.1007/s12035-018-1346-8</article-id>
<article-id pub-id-type="manuscript">NIHMS1508935</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuron type-specific loss of CDKL5 leads to alterations in mTOR signaling and synaptic markers</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Schroeder</surname>
<given-names>Ethan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yuan</surname>
<given-names>Li</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Seong</surname>
<given-names>Eunju</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ligon</surname>
<given-names>Cheryl</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>DeKorver</surname>
<given-names>Nicholas</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gurumurthy</surname>
<given-names>C.B.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arikkath</surname>
<given-names>Jyothi</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">#</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska – 68198.</aff>
<aff id="A2"><label>2</label>Developmental Neuroscience, Munroe-Meyer Institute, University of Nebraska Medical Center, Omaha, Nebraska – 68198.</aff>
<aff id="A3"><label>3</label>Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska – 68198.</aff>
<author-notes>
<corresp id="CR1"><label>#</label>- To whom correspondence should be addressed: – <email>Jyothi.arikkath@unmc.edu</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P33"><bold>Conflict of interest:</bold> The authors declare that they have no conflicts of interest with the contents of this article.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>5</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>04</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>6</month>
<year>2020</year>
</pub-date>
<volume>56</volume>
<issue>6</issue>
<fpage>4151</fpage>
<lpage>4162</lpage>
<!--elocation-id from pubmed: 10.1007/s12035-018-1346-8-->
<abstract id="ABS1">
<p id="P1">CDKL5 disorder is a devastating neurodevelopmental disorder associated with epilepsy, developmental retardation, autism and related phenotypes. Mutations in the <italic>CDKL5</italic> gene, encoding CDKL5, have been identified in this disorder. CDKL5 is a protein with homology to the serine-threonine kinases and incompletely characterized function. We generated and validated a murine model bearing a floxed allele of <italic>CDKL5</italic> and polyclonal antibodies to CDKL5. CDKL5 is well expressed in the cortex, hippocampus and striatum, localized to synaptosomes and nuclei and developmentally regulated in the hippocampus. Using Cre- mediated mechanisms, we deleted CDKL5 from excitatory CaMKIIα positive neurons or inhibitory GABAergic neurons. Our data indicate that loss of CDKL5 in excitatory neurons of the cortex or inhibitory neurons of the striatum differentially alters expression of some components of the mTOR signaling pathway. Further loss of CDKL5 in excitatory neurons of the cortex or inhibitory neurons of the striatum leads to alterations in levels of synaptic markers in a neuron-type specific manner. Taken together, these data support a model in which loss of CDKL5 alters mTOR signaling and synaptic compositions in a neuron type specific manner and suggest that CDKL5 may have distinct functional roles related to cellular signaling in excitatory and inhibitory neurons. Thus, these studies provide new insights into the biology of CDKL5 and suggest that the molecular pathology in CDKL5 disorder may have distinct neuron-type specific origins and effects.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>